Tech Company Financing Transactions

Taligen Therapeutics Funding Round

Taligen Therapeutics, based in Aurora, raised $65 million in investment from Alta Partners, Clarus and High Country Venture.

Transaction Overview

Company Name
Taligen Therapeutics
Announced On
2/1/2008
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors

Alta Partners (Lead Investor) (Ed Hurwitz)

Clarus (Lead Investor) (Nick Galakatos)

High Country Venture

Sanderling Ventures (Timothy Mills)

Proceeds Purpose
Timothy Mills, PhD., Chairman of the Board of Taligen said, "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12635 East Montview Blvd 223
Aurora, CO 80045
USA
Phone
720.859.4056
Website
www.taligentherapeutics.com
Email Address
[email protected]
Overview
Taligen's lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response.
Profile
Taligen Therapeutics LinkedIn Company Profile
Social Media
Taligen Therapeutics Company Twitter Account
Company News
Taligen Therapeutics News
Facebook
Taligen Therapeutics on Facebook
YouTube
Taligen Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Abbie Celniker
  Abbie Celniker LinkedIn Profile  Abbie Celniker Twitter Account  Abbie Celniker News  Abbie Celniker on Facebook
Chief Scientific Officer
Michael Holers
  Michael Holers LinkedIn Profile  Michael Holers Twitter Account  Michael Holers News  Michael Holers on Facebook
President
Woodruff Emlen
  Woodruff Emlen LinkedIn Profile  Woodruff Emlen Twitter Account  Woodruff Emlen News  Woodruff Emlen on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/1/2008: ZillionTV venture capital transaction
Next: 2/1/2008: GlobalScholar venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.